分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Selective Induction of Mitochondrial Fragmentation for Cancer Immunotherapy via mtDNA-Targeting AIE Photosensitizer

Wen-Jin Wang, Ying-Xin Hao, Yu-Meng Wang, Zhuo-Yang Xin, Man Zhang, Hao-Tian Xin, Jing Feng, Kang Li, Zheng Zhao, Ben Zhong Tang, Kang-Nan Wang

Journal:BIOMATERIALS

IF:13.6

DOI:10.1016/j.biomaterials.2026.124211

PMID:42025044

Published:2026-04-15

research field:线粒体生物学癌症研究光动力治疗分子成像免疫治疗

Abstract

Mitochondrial damage in tumor cells has recently emerged as a mechanism of immunogenic cell death, with precise triggers acting as potent antitumor immunostimulants. Here, we developed PyTPAMa, an asymmetric AIE-active photosensitizer that selectively accumulates in mitochondria and binds mitochondrial DNA (mtDNA) and induces mitochondrial fragmentation to trigger strong immunostimulation. Upon light activation, PyTPAMa generates a spatially confined, hybrid Type I/II ROS burst that disrupts the mitochondrial network, causing mitochondrial fragmentation, opening the mitochondrial permeability transition pore, and releasing mtDNA into the cytosol. This activates the NLRP3-GSDMD inflammasome, initiating pyroptosis and orchestrating systemic antitumor immunity. RNA sequencing reveals widespread silencing of mitochondrial genes and reprogramming of the NLRP3 inflammasome and antigen-presentation pathways. As a programmable immune ignition switch, PyTPAMa induces immunogenic cell death in vitro, transforms distant “cold” tumors into immune-infiltrated lesions in vivo, and achieves 96% suppression of bilateral 4T1 tumors without systemic toxicity. This work establishes mitochondrial fragmentation as a programmable immune switch and validates PyTPAMa for fragmentation-driven cancer immunotherapy.

本文使用的Yeasen产品

购物车
客服
转染试用